A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation (CRISTALLO)

  • STATUS
    Recruiting
  • End date
    May 31, 2024
  • participants needed
    165
  • sponsor
    Hoffmann-La Roche
Updated on 18 June 2022
platelet count
lymphoid leukemia
fludarabine
cyclophosphamide
chronic lymphocytic leukemia
rituximab
cytopenia
venetoclax
TP53
neutrophil count
bendamustine
obinutuzumab

Summary

This study will evaluate the efficacy and safety of venetoclax and obinutuzumab (VEN + G) compared with fludarabine + cyclophosphamide + rituximab or bendamustine + rituximab (FCR/BR) in FIT participants (FIT is defined by a cumulative illness rating scale [CIRS]/score of ≤6 and a normal creatinine clearance of ≥70 mL/min) with previously untreated CLL without DEL(17P) or TP53 mutation requiring treatment. Eligible participants will be randomly assigned in a 1:1 ratio to receive either VEN + G (Arm A) or FCR/BR (Arm B).

Details
Condition Chronic Lymphocytic Leukemia (CLL)
Treatment Rituximab, cyclophosphamide, Fludarabine, Obinutuzumab, Bendamustine, venetoclax
Clinical Study IdentifierNCT04285567
SponsorHoffmann-La Roche
Last Modified on18 June 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Ability to comply with the study protocol, in the investigator's judgment
Aged 18 years or older
Have previously untreated documented Chronic Lymphocytic Leukemia (CLL) according to the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
CLL requiring treatment according to the iwCLL criteria
Cumulative Illness Rating Scale (CIRS) score ≤ 6 and creatinine clearance (CrCl) ≥ 70 mL/min
Hematology values within the following limits, unless cytopenia is caused by the underlying disease (i.e., no evidence of additional bone marrow (BM) dysfunction; e.g., myelodysplastic syndrome, hypoplastic BM)
Absolute neutrophil count ≥ 1.0 x 109/L, unless there is BM involvement
Platelet count ≥ 75 x 109/L and more than 7 days since last transfusion, or ≥ 30 x 109/L if there is BM involvement
Adequate liver function as indicated by a total bilirubin, aspartate aminotransferase
Life expectancy >6 months
and Alanine transaminase ≤ 2 times the institutional upper limit of normal
For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception and agreement to refrain from donating eggs
(ULN) value, unless directly attributable to the participant's CLL
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating sperm

Exclusion Criteria

Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL)
Participants with Small Lymphocyclic Lymphoma (SLL) only
Known central nervous system involvement
Participants with a history of confirmed progressive multifocal leukoencephalopathy (PML)
Detected del(17p) or TP53 mutation (valid test within 6-months from screening is required for randomisation)
An individual organ/system impairment score of 4 as assessed by the Cumulative Illness Rating Scale (CIRS) definition limiting the ability to receive the treatment regimen of this trial with the exception of eyes, ears, nose, throat organ system
Participants with uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
History of prior malignancy
Participants with infections requiring IV treatment (Grade 3 or 4) within the last 8 weeks prior to enrollment
Evidence of other clinically significant uncontrolled conditions including but not limited to active or uncontrolled systemic infection (e.g., viral, bacterial, or fungal)
History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine products
Hypersensitivity to fludarabine, bendamustine, cyclophosphamide, rituximab, obinutuzumab, or venetoclax or to any of the excipients (e.g., trehalose)
Pregnant women and nursing mothers
Prisoners or participants who are institutionalized by regulatory or court order or persons who are in dependence to the Sponsor or an investigator
Vaccination with a live vaccine ≤ 28 days prior to randomization
History of illicit drug or alcohol abuse within 12 months prior to screening, in the investigator's judgment
Positive test results for chronic hepatitis B virus (HBV) infection (defined as positive hepatitis B surface antigen [HBsAg] serology)
Positive test result for hepatitis C (hepatitis C virus [HCV] antibody serology testing)
Participants with known infection with HIV or Human T-Cell Leukemia Virus 1 (HTLV-1)
Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the participant's safe participation in and completion of the study
Received any of the following agents within 28 days prior to the first dose of study
treatment
Immunotherapy
Radiotherapy
Hormone therapy
Any therapies intended for the treatment of lymphoma/leukemia whether approved or experimental
Participants who have received the following agents
Strong and moderate CYP3A inhibitors/inducers within 7 days prior to the initiation of study treatment
Steroid therapy for anti-neoplastic intent with the exception of inhaled steroids for asthma, topical steroids, or replacement/stress corticosteroids within 7 days prior to the first dose of study drug administration
Consumed grapefruit, grapefruit products, Seville oranges(including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of study drug and throughout venetoclax administration
Inability to swallow a large number of tablets
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note